ACE
EstablishedACE is a serum enzyme marker used mainly to support diagnosis and monitoring of sarcoidosis.
ACE is a blood marker most useful for monitoring sarcoidosis, an inflammatory condition that forms clusters of immune cells called granulomas. Levels usually rise when granulomas are active and fall with treatment, but the test alone can't diagnose the disease and is affected by common blood pressure medications.
Angiotensin-converting enzyme (ACE) is an acid glycoprotein produced mainly by activated alveolar macrophages and epithelioid cells of granulomas. It converts angiotensin I to angiotensin II and is best known clinically as a biomarker of granulomatous inflammation rather than for its role in blood pressure regulation.
Serum ACE is elevated in most patients with active sarcoidosis, correlating with granuloma burden, and is the only biomarker named in WASOG international sarcoidosis guidelines, though its sensitivity and specificity are limited. Elevated ACE has also been reported in Gaucher disease, tuberculosis, silicosis, Hodgkin lymphoma, and hyperthyroidism.
Measured by serum immunoassay; a 2025-2026 study proposed a cutoff of ≥50 IU/L associated with multi-organ sarcoidosis involvement. ACE-inhibitor medications (used for hypertension) suppress serum ACE and produce falsely low readings, a major confounder given how common these drugs are.
Serial ACE levels can track disease activity and response to immunosuppressive therapy in sarcoidosis, with levels typically declining after treatment initiation, though it should not be used as the sole basis for diagnosis or treatment decisions.
Elevated in active granulomatous disease, especially sarcoidosis; low sensitivity/specificity limits standalone diagnostic use.
- Valeyre, D., Bernardinello, N., Righetti, G., et al. (2023-2026). Re-evaluating serum angiotensin-converting enzyme in sarcoidosis. PMC.
- WASOG Sarcoidosis Organ Assessment Instrument (updated clinical tool).